Reversal of drug resistance by exposure of MCF-7 or MCF-7/CDDP human breast carcinoma cells to SR-4233 or etanidazole under hypoxic conditions

T. Kusumoto, B. A. Teicher, S. A. Holden, C. N. Coleman, S. Liu, E. A. Sotomayor

Research output: Contribution to journalArticle

Abstract

Drug resistance is a major problem in cancer therapy. The MCF-7/CDDP cell line, a subline of the MCF-7 human breast carcinoma cell line which is resistant to cis-diamminedichloroplatinum(II), is also resistant to carboplatin, D-tetraplatin and to a lesser degree to melphalan, thiotepa and BCNU compared with the MCF-7 parental cell line. This resistance persists both under normally oxygenated conditions and after 2 h of exposure to hypoxic conditions prior to exposure to the antitumor alkylating agents under normally oxygenated conditions. When the MCF-7 parental cells and MCF-7/CDDP cells were treated with SR-4233 (20 μM) or etanidazole (5 mM) for 2 h prior to and during exposure to the antitumor alkylating agents there was no change in the sensitivity and resistance patterns of the cell lines. However, if the MCF-7 parental cells and the MCF-7/CDDP cells were exposed to SR-4233 (20 μM) or etanidazole (5 mM) for 2 h under hypoxic conditions followed by release of the hypoxia and exposure to the antitumor alkylating agents for 1 h under normally oxygenated conditions the resistance of the MCF-7/CDDP was reversed so that both the MCF-7 parental and MCF-7/CDDP cell lines were essentially equally sensitive to the six antitumor alkylating agents. These results indicate that non-cytotoxic concentrations of modulators such as SR- 4233 or etanidazole may be useful in reversing resistance to the antitumor alkylating agents in solid tumors with significant hypoxic fractions.

Original languageEnglish (US)
Pages (from-to)205-211
Number of pages7
JournalInternational Journal of Oncology
Volume3
Issue number2
StatePublished - 1993
Externally publishedYes

Fingerprint

tirapazamine
Etanidazole
MCF-7 Cells
Drug Resistance
Alkylating Agents
Breast Neoplasms
Antineoplastic Agents
Cell Line
ormaplatin
Thiotepa
Carmustine
Melphalan
Carboplatin
Cisplatin
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Reversal of drug resistance by exposure of MCF-7 or MCF-7/CDDP human breast carcinoma cells to SR-4233 or etanidazole under hypoxic conditions. / Kusumoto, T.; Teicher, B. A.; Holden, S. A.; Coleman, C. N.; Liu, S.; Sotomayor, E. A.

In: International Journal of Oncology, Vol. 3, No. 2, 1993, p. 205-211.

Research output: Contribution to journalArticle

Kusumoto, T. ; Teicher, B. A. ; Holden, S. A. ; Coleman, C. N. ; Liu, S. ; Sotomayor, E. A. / Reversal of drug resistance by exposure of MCF-7 or MCF-7/CDDP human breast carcinoma cells to SR-4233 or etanidazole under hypoxic conditions. In: International Journal of Oncology. 1993 ; Vol. 3, No. 2. pp. 205-211.
@article{52f99261bb214a79b474f1ee29400ef2,
title = "Reversal of drug resistance by exposure of MCF-7 or MCF-7/CDDP human breast carcinoma cells to SR-4233 or etanidazole under hypoxic conditions",
abstract = "Drug resistance is a major problem in cancer therapy. The MCF-7/CDDP cell line, a subline of the MCF-7 human breast carcinoma cell line which is resistant to cis-diamminedichloroplatinum(II), is also resistant to carboplatin, D-tetraplatin and to a lesser degree to melphalan, thiotepa and BCNU compared with the MCF-7 parental cell line. This resistance persists both under normally oxygenated conditions and after 2 h of exposure to hypoxic conditions prior to exposure to the antitumor alkylating agents under normally oxygenated conditions. When the MCF-7 parental cells and MCF-7/CDDP cells were treated with SR-4233 (20 μM) or etanidazole (5 mM) for 2 h prior to and during exposure to the antitumor alkylating agents there was no change in the sensitivity and resistance patterns of the cell lines. However, if the MCF-7 parental cells and the MCF-7/CDDP cells were exposed to SR-4233 (20 μM) or etanidazole (5 mM) for 2 h under hypoxic conditions followed by release of the hypoxia and exposure to the antitumor alkylating agents for 1 h under normally oxygenated conditions the resistance of the MCF-7/CDDP was reversed so that both the MCF-7 parental and MCF-7/CDDP cell lines were essentially equally sensitive to the six antitumor alkylating agents. These results indicate that non-cytotoxic concentrations of modulators such as SR- 4233 or etanidazole may be useful in reversing resistance to the antitumor alkylating agents in solid tumors with significant hypoxic fractions.",
author = "T. Kusumoto and Teicher, {B. A.} and Holden, {S. A.} and Coleman, {C. N.} and S. Liu and Sotomayor, {E. A.}",
year = "1993",
language = "English (US)",
volume = "3",
pages = "205--211",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Reversal of drug resistance by exposure of MCF-7 or MCF-7/CDDP human breast carcinoma cells to SR-4233 or etanidazole under hypoxic conditions

AU - Kusumoto, T.

AU - Teicher, B. A.

AU - Holden, S. A.

AU - Coleman, C. N.

AU - Liu, S.

AU - Sotomayor, E. A.

PY - 1993

Y1 - 1993

N2 - Drug resistance is a major problem in cancer therapy. The MCF-7/CDDP cell line, a subline of the MCF-7 human breast carcinoma cell line which is resistant to cis-diamminedichloroplatinum(II), is also resistant to carboplatin, D-tetraplatin and to a lesser degree to melphalan, thiotepa and BCNU compared with the MCF-7 parental cell line. This resistance persists both under normally oxygenated conditions and after 2 h of exposure to hypoxic conditions prior to exposure to the antitumor alkylating agents under normally oxygenated conditions. When the MCF-7 parental cells and MCF-7/CDDP cells were treated with SR-4233 (20 μM) or etanidazole (5 mM) for 2 h prior to and during exposure to the antitumor alkylating agents there was no change in the sensitivity and resistance patterns of the cell lines. However, if the MCF-7 parental cells and the MCF-7/CDDP cells were exposed to SR-4233 (20 μM) or etanidazole (5 mM) for 2 h under hypoxic conditions followed by release of the hypoxia and exposure to the antitumor alkylating agents for 1 h under normally oxygenated conditions the resistance of the MCF-7/CDDP was reversed so that both the MCF-7 parental and MCF-7/CDDP cell lines were essentially equally sensitive to the six antitumor alkylating agents. These results indicate that non-cytotoxic concentrations of modulators such as SR- 4233 or etanidazole may be useful in reversing resistance to the antitumor alkylating agents in solid tumors with significant hypoxic fractions.

AB - Drug resistance is a major problem in cancer therapy. The MCF-7/CDDP cell line, a subline of the MCF-7 human breast carcinoma cell line which is resistant to cis-diamminedichloroplatinum(II), is also resistant to carboplatin, D-tetraplatin and to a lesser degree to melphalan, thiotepa and BCNU compared with the MCF-7 parental cell line. This resistance persists both under normally oxygenated conditions and after 2 h of exposure to hypoxic conditions prior to exposure to the antitumor alkylating agents under normally oxygenated conditions. When the MCF-7 parental cells and MCF-7/CDDP cells were treated with SR-4233 (20 μM) or etanidazole (5 mM) for 2 h prior to and during exposure to the antitumor alkylating agents there was no change in the sensitivity and resistance patterns of the cell lines. However, if the MCF-7 parental cells and the MCF-7/CDDP cells were exposed to SR-4233 (20 μM) or etanidazole (5 mM) for 2 h under hypoxic conditions followed by release of the hypoxia and exposure to the antitumor alkylating agents for 1 h under normally oxygenated conditions the resistance of the MCF-7/CDDP was reversed so that both the MCF-7 parental and MCF-7/CDDP cell lines were essentially equally sensitive to the six antitumor alkylating agents. These results indicate that non-cytotoxic concentrations of modulators such as SR- 4233 or etanidazole may be useful in reversing resistance to the antitumor alkylating agents in solid tumors with significant hypoxic fractions.

UR - http://www.scopus.com/inward/record.url?scp=0027319876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027319876&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 205

EP - 211

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 2

ER -